Latest advances in cannabinoid receptor agonists

Bibliography

• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61-5
   PubMed Web of Science ®Google Scholar
• Shire D, Calandra B, Rinaldi-Carmona M, Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1996;1307(2):132-6
   PubMedGoogle Scholar
• Gerard CM, Mollereau C, Vassart G, Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279(Pt 1):129-34
   PubMedGoogle Scholar
• Griffin G, Tao Q, Abood ME. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 2000;292(3):886-94
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn AB, Little MD, Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87(5):1932-6
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI, International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54(2):161-202
   PubMed Web of Science ®Google Scholar
• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58(3):389-462
   PubMed Web of Science ®Google Scholar
• Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008;20(Suppl 1):10-4
   PubMed Web of Science ®Google Scholar
• Kunos G, Osei-Hyiaman D, Batkai S, Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 2009;30(1):1-7
   PubMed Web of Science ®Google Scholar
• Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999;58(4):315-48
   PubMed Web of Science ®Google Scholar
• Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 2009;11:e3
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Duncan M, Kingsley PJ, Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310(5746):329-32
   PubMed Web of Science ®Google Scholar
• Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008;153(2):319-34
   PubMed Web of Science ®Google Scholar
• Demuth DG, Molleman A. Cannabinoid signalling. Life Sci 2006;78(6):549-63
   PubMed Web of Science ®Google Scholar
• Price MR, Baillie GL, Thomas A, Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005;68(5):1484-95
   PubMed Web of Science ®Google Scholar
• Horswill JG, Bali U, Shaaban S, PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 2007;152(5):805-14
   PubMed Web of Science ®Google Scholar
• Navarro HA, Howard JL, Pollard GT, Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 2009;156(7):1178-84
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152(7):1092-101
   PubMed Web of Science ®Google Scholar
• Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007;152(5):567-75
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G, Davies WL, In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006;27(1):1-4
   PubMed Web of Science ®Google Scholar
• Begg M, Pacher P, Batkai S, Evidence for novel cannabinoid receptors. Pharmacol Ther 2005;106(2):133-45
   PubMed Web of Science ®Google Scholar
• Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002;296(5568):678-82
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946-9
   PubMed Web of Science ®Google Scholar
• Hanus L, Abu-Lafi S, Fride E, 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001;98(7):3662-5
   PubMed Web of Science ®Google Scholar
• Porter A-C, Sauer J-M, Knierman M-D, Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002;301(3):1020-4
   PubMed Web of Science ®Google Scholar
• Huang SM, Bisogno T, Petros TJ, Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 2001;276(46):42639-44
   PubMed Web of Science ®Google Scholar
• Burstein SH, Huang SM, Petros TJ, Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol 2002;64(7):1147-50
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50(1):83-90
   PubMed Web of Science ®Google Scholar
• Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006; 30:(Suppl 1):S7-S12
   Google Scholar
• Beltramo M, Stella N, Calignano A, Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997;277(5329):1094-7
   PubMed Web of Science ®Google Scholar
• Piomelli D, Beltramo M, Glasnapp S, Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 1999;96(10):5802-7
   PubMed Web of Science ®Google Scholar
• Fegley D, Kathuria S, Mercier R, Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 2004;101(23):8756-61
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Hermann A, Glaser ST, Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J Biol Chem 2006;281(14):9066-75
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Glaser ST, Deutsch DG. Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci USA 2009;106(15):6375-80
   PubMed Web of Science ®Google Scholar
• Saario SM, Laitinen JT. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol 2007;101(5):287-93
   PubMed Web of Science ®Google Scholar
• Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008;8(3):247-67
   PubMed Web of Science ®Google Scholar
• Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007;14(12):1347-56
   PubMedGoogle Scholar
• Kozak KR, Marnett LJ. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):211-20
   PubMed Web of Science ®Google Scholar
• Rouzer CA, Marnett LJ. Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J Biol Chem 2008;283(13):8065-9
   PubMed Web of Science ®Google Scholar
• Palczewski K, Kumasaka T, Hori T, Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000;289(5480):739-45
   PubMed Web of Science ®Google Scholar
• Cherezov V, Rosenbaum DM, Hanson MA, High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007;318(5854):1258-65
   PubMed Web of Science ®Google Scholar
• Park JH, Scheerer P, Hofmann KP, Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008;454(7201):183-7
   PubMed Web of Science ®Google Scholar
• Picone RP, Khanolkar AD, Xu W, (-)-7′-Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol 2005;68(6):1623-35
   PubMed Web of Science ®Google Scholar
• Pei Y, Mercier RW, Anday JK, Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol 2008;15(11):1207-19
   PubMedGoogle Scholar
• Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008;13(2):147-59
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156(3):397-411
   PubMed Web of Science ®Google Scholar
• Lu D, Vemuri VK, Duclos RI Jr, The cannabinergic system as a target for anti-inflammatory therapies. Curr Top Med Chem 2006;6(13):1401-26
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971;93(1):217-24
   PubMed Web of Science ®Google Scholar
• Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 2008;4(1):99-107
   PubMedGoogle Scholar
• Skrabek RQ, Galimova L, Ethans K, Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9(2):164-73
   PubMed Web of Science ®Google Scholar
• Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009;15(1):84-8
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov NCT ID: NCT00217971. [Last accessed 16 October 2009]
   Google Scholar
• Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30(3):271-80
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Jia W, Schlomer J, Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 2006;70(3):897-908
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Peters M, Murillo-Rodriguez E, Cannabidiol–recent advances. Chem Biodivers 2007;4(8):1678-92
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008;153(2):199-215
   PubMed Web of Science ®Google Scholar
• Russo EB, Burnett A, Hall B, Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005;30(8):1037-43
   PubMed Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134(4):845-52
   PubMed Web of Science ®Google Scholar
• Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006;103(20):7895-900
   PubMed Web of Science ®Google Scholar
• Burstein S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J 2005;7(1):E143-8
   Web of Science ®Google Scholar
• Burstein SH, Karst M, Schneider U, Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci 2004;75(12):1513-22
   PubMed Web of Science ®Google Scholar
• Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 2009;11(1):109-119
   PubMed Web of Science ®Google Scholar
• Rhee MH, Vogel Z, Barg J, Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997;40(20):3228-33
   PubMed Web of Science ®Google Scholar
• Ambrosio AL, Dias SM, Polikarpov I, Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J Biol Chem 2007;282(25):18625-33
   PubMed Web of Science ®Google Scholar
• Zurier RB, Rossetti RG, Lane JH, Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 1998;41(1):163-70
   PubMedGoogle Scholar
• Vann RE, Cook CD, Martin BR, Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007;320(2):678-86
   PubMed Web of Science ®Google Scholar
• Devane WA, Dysarz FA III, Johnson MR, Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34(5):605-13
   PubMed Web of Science ®Google Scholar
• Thakur GA, Nikas SP, Li C, Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol 2005(168):209-46
   PubMedGoogle Scholar
• Lu D, Meng Z, Thakur GA, Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem 2005;48(14):4576-85
   PubMed Web of Science ®Google Scholar
• Luk T, Jin W, Zvonok A, Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 2004;142(3):495-500
   PubMed Web of Science ®Google Scholar
• Papahatjis DP, Nikas SP, Andreou T, Novel 1′,1′-chain substituted delta(8)-tetrahydrocannabinols. Bioorg Med Chem Lett 2002;12(24):3583-6
   PubMed Web of Science ®Google Scholar
• Papahatjis DP, Nikas SP, Kourouli T, Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1′. J Med Chem 2003;46(15):3221-9
   PubMed Web of Science ®Google Scholar
• Papahatjis DP, Nahmias VR, Nikas SP, C1′-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. J Med Chem 2007;50(17):4048-60
   PubMed Web of Science ®Google Scholar
• Krishnamurthy M, Ferreira AM, Moore BM II. Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. Bioorg Med Chem Lett 2003;13(20):3487-90
   PubMed Web of Science ®Google Scholar
• Nadipuram AK, Krishnamurthy M, Ferreira AM, Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors. Bioorg Med Chem 2003;11(14):3121-32
   PubMed Web of Science ®Google Scholar
• Drake DJ, Jensen RS, Busch-Petersen J, Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues. J Med Chem 1998;41(19):3596-608
   PubMed Web of Science ®Google Scholar
• Harrington PE, Stergiades IA, Erickson J, Synthesis of functionalized cannabinoids. J Org Chem 2000;65(20):6576-82
   PubMed Web of Science ®Google Scholar
• Thakur GA, Palmer SL, Harrington PE, Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. J Biochem Biophys Methods 2002;54(1-3):415-22
   PubMedGoogle Scholar
• Dewey WL, Martin BR, May EL. Cannabinoid stereoisomers: pharmacological effects. CRC Handb Stereoisomers Drugs Psychopharmacol 1984:317-26
   Google Scholar
• Martin BR, Balster RL, Razdan RK, Behavioral comparisons of the stereoisomers of tetrahydrocannabinols. Life Sci 1981;29(6):565-74
   PubMed Web of Science ®Google Scholar
• Hanus LO, Tchilibon S, Ponde DE, Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem 2005;3(6):1116-23
   PubMed Web of Science ®Google Scholar
• Fride E, Ponde D, Breuer A, Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Neuropharmacology 2005;48(8):1117-29
   PubMed Web of Science ®Google Scholar
• Ben-Shabat S, Hanus LO, Katzavian G, New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 2006;49(3):1113-7
   PubMed Web of Science ®Google Scholar
• Mauler F, Mittendorf J, Horvath E, Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 2002;302(1):359-68
   PubMed Web of Science ®Google Scholar
• Mauler F, Hinz V, Augstein KH, Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res. 2003;989(1):99-111
   PubMed Web of Science ®Google Scholar
• Mauler F, Horvath E, De Vry J, BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev 2003;9(4):343-58
   PubMedGoogle Scholar
• Hillard CJ, Manna S, Greenberg MJ, Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 1999;289(3):1427-33
   PubMed Web of Science ®Google Scholar
• Abadji V, Lin S, Taha G, (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994;37(12):1889-93
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bisogno T, De Petrocellis L, Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor “hybrid” ligands. Biochem Biophys Res Commun 2001;281(2):444-51
   PubMed Web of Science ®Google Scholar
• Gareau Y, Dufresne C, Gallant M, Structure activity relationship of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett 1996;6(2):189-94
   Web of Science ®Google Scholar
• Huffman JW, Liddle J, Yu S, 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 1999;7(12):2905-14
   PubMed Web of Science ®Google Scholar
• Martin BR, Wiley JL, Beletskaya I, Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther 2006;318(3):1230-9
   PubMed Web of Science ®Google Scholar
• Hanus L, Breuer A, Tchilibon S, HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci. USA 1999;96(25):14228-33
   PubMed Web of Science ®Google Scholar
• Makriyannis A, Khanolkar A. Bicyclic cannabinoid agonists for the cannabinoid receptor. International Patent Appl. PCT/US00/41238; 2000
   Google Scholar
• Khanolkar AD, Lu D, Ibrahim M, Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 2007;50(26):6493-500
   PubMed Web of Science ®Google Scholar
• Rahn EJ, Zvonok AM, Thakur GA, Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 2008;327(2):584-91
   PubMed Web of Science ®Google Scholar
• Bell MR, D'Ambra TE, Kumar V, Antinociceptive (aminoalkyl)indoles. J Med Chem 1991;34:1099-100
   PubMed Web of Science ®Google Scholar
• Eissenstat MA, Bell MR, D'Ambra TE, Aminoalkylindoles (AAIs): structurally novel cannabinoid-mimetics. NIDA Res Monogr 1991;105:427-8
   Google Scholar
• D'Ambra TE, Estep KG, Bell MR, Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992;35(1):124-35
   PubMed Web of Science ®Google Scholar
• Eissenstat MA, Bell MR, D'Ambra TE, Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 1995;38(16):3094-105
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Deng H, Zvonok A, Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003;100(18):10529-33
   PubMed Web of Science ®Google Scholar
• Malan TP Jr, Ibrahim MM, Deng H, CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001;93(3):239-45
   PubMed Web of Science ®Google Scholar
• Yao BB, Mukherjee S, Fan Y, In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 2006;149(2):145-54
   PubMed Web of Science ®Google Scholar
• Marriott KS, Huffman JW. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr Top Med Chem 2008;8(3):187-204
   PubMed Web of Science ®Google Scholar
• Showalter VM, Compton DR, Martin BR, Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996;278(3):989-99
   PubMed Web of Science ®Google Scholar
• Frost JM, Dart MJ, Tietje KR, Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. J Med Chem 2008;51(6):1904-12
   PubMed Web of Science ®Google Scholar
• Yao BB, Hsieh G, Daza AV, Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 2009;328(1):141-51
   PubMed Web of Science ®Google Scholar
• Yao BB, Hsieh GC, Frost JM, In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 2008;153(2):390-401
   PubMed Web of Science ®Google Scholar
• Gallant M, Dufresne C, Gareau Y, New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 1996;6(19):2263-8
   Web of Science ®Google Scholar
• Valenzano KJ, Tafesse L, Lee G, Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005;48(5):658-72
   PubMed Web of Science ®Google Scholar
• Murineddu G, Lazzari P, Ruiu S, Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c ]pyrazole-3-carboxamide. J Med Chem 2006;49(25):7502-12
   PubMed Web of Science ®Google Scholar
• Giblin GM, O'Shaughnessy CT, Naylor A, Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 2007;50(11):2597-600
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov. NCT ID: NCT00444769. [Last accessed 16 October 2009]
   Google Scholar
• Available from: www.clinicaltrials.gov. NCT ID: NCT00447486. [Last accessed 16 October 2009]
   Google Scholar
• Available from: www.clinicaltrials.gov. NCT ID: NCT00479427. [Last accessed 16 October 2009]
   Google Scholar
• Available from: www.clinicaltrials.gov. NCT ID: NCT00511524. [Last accessed 16 October 2009]
   Google Scholar
• Manera C, Benetti V, Castelli MP, Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J Med Chem 2006;49(20):5947-57
   PubMed Web of Science ®Google Scholar
• Manera C, Cascio MG, Benetti V, New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett 2007;17(23):6505-10
   PubMed Web of Science ®Google Scholar
• Ferrarini PL, Calderone V, Cavallini T, Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. Bioorg Med Chem 2004;12(8):1921-33
   PubMed Web of Science ®Google Scholar
• Stern E, Muccioli GG, Bosier B, Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality. J Med Chem 2007;50(22):5471-84
   PubMed Web of Science ®Google Scholar
• Stern E, Muccioli GG, Millet R, Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J Med Chem 2006;49(1):70-9
   PubMed Web of Science ®Google Scholar
• Diaz P, Xu J, Astruc-Diaz F, Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J Med Chem 2008;51(16):4932-47
   PubMed Web of Science ®Google Scholar
• Diaz P, Phatak SS, Xu J, 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. J Med Chem 2009;52(2):433-44
   PubMed Web of Science ®Google Scholar
• Gardin A, Kucher K, Kiese B, CRA13, a Novel Cannabinoid agonist: first in human pharmacokinetics and safety. Drug Metab Dispos 2009;37(4):827-33
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Shackleford DM, Charman WN, Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res 2009;26(6):1486-95
   PubMed Web of Science ®Google Scholar
• Ohta H, Ishizaka T, Tatsuzuki M, Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorg Med Chem 2008;16(3):1111-24
   PubMed Web of Science ®Google Scholar
• Omura H, Kawai M, Shima A, The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives. Bioorg Med Chem Lett 2008;18(11):3310-4
   PubMed Web of Science ®Google Scholar
• Solvay Pharmaceuticals BV, Neth. Preparation of 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators. WO2008152086; 2008
   Google Scholar
• Solvay Pharmaceuticals BV, Neth. Preparation of 5-aryl-4,5-dihydro-(1H)-pyrazoles as cannabinoid CB1 receptor agonists. WO2009037244; 2009
   Google Scholar
• Solvay Pharmaceuticals BV, Neth. 4,5-Dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. WO2001070700; 2001
   Google Scholar
• Organon NV, Neth. Preparation of indole derivatives for treatment of pain. WO2008101995; 2008
   Google Scholar
• Astrazeneca AB, Swed. Tetrahydro-1H-pyrido[3,4-b]indole derivatives as CB1 receptor ligands and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008036022; 2008
   Google Scholar
• Astrazeneca AB, Swed., Astrazeneca UK Limited. Preparation of substituted tetrahydrocarbazole for use as analgesicsWO2009024819; 2009
   Google Scholar
• Pfizer Products, Inc., USA. Benzimidazolone derivatives and their preparation, pharmaceutical compositions and use in the treatment of CB1 and CB2 receptor mediated diseases. WO2008032164; 2008
   Google Scholar
• Abbott Laboratories, USA. Preparation of heterocyclyl carboxamides as cannabinoid receptor ligands. WO2009009550; 2009
   Google Scholar
• Abbott Laboratories, USA. Novel compounds as cannabinoid receptor ligands. US2008287510; 2008
   Google Scholar
• Abbott Laboratories, USA. Thiazolylidene derivatives as cannabinoid receptor ligands and their preparation, pharmaceutical compositions and use in the treatment of diseases. US2008242654; 2008
   Google Scholar
• Abbott Laboratories, USA. Preparation of N-(thiazolylidene)carboxamide derivatives as cannabinoid receptor ligands. WO2009067613; 2009
   Google Scholar
• Abbott Laboratories, USA. Preparation of isothiazolylidene containing compounds as therapeutic cannabinoid receptor ligands. WO2008130953; 2008
   Google Scholar
• Abbott Laboratories, USA. Preparation of thiazoles and thiadiazoles as cannabinoid receptor ligands. WO2008063781; 2008
   Google Scholar
• Abbott Laboratories, USA. Thienofuran derivatives as CB2 cannabinoid receptor ligands and their preparation, pharmaceutical compositions and use in the treatment of pain. WO2008028094; 2008
   Google Scholar
• Abbott Laboratories. Preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compounds as therapeutic cannabinoid receptor ligands. WO2009048936; 2009
   Google Scholar
• Abbott Laboratories, USA. Thiophene derivatives as CB2 cannabinoid receptor ligands and their preparation, pharmaceutical compositions and use in the treatment of pain. WO2008028093; 2008
   Google Scholar
• Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG. Preparation of diazepanes as CB2 receptor modulators for treating inflammation, pain, and other diseases. WO2008064054; 2008
   Google Scholar
• Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG. Diazepane compounds CB2 receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2009055357; 2009
   Google Scholar
• Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG. Preparation of morpholinylmethylpyridinylamine derivatives as modulators of CB2 receptor. WO2008048914; 2008
   Google Scholar
• Zindell R, Riether D, Bosanac T, Morpholine containing CB2 selective agonists. Bioorg Med Chem Lett 2009;19(6):1604-9
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG. 2-Sulfonyl carboxamide compounds which modulate the CB2 receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008039645; 2008
   Google Scholar
• Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG. Preparation of N-heteroaryl-2-[benzenesulfonyl (or pyridinesulfonyl)] amides which modulate the CB2 receptor. WO2008014199; 2008
   Google Scholar
• Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG. Preparation of 2-sulfamoyl-2-methylpropionamides as CB2 receptor modulators for treating diseases. WO2009061652; 2009
   Google Scholar
• Acadia Pharmaceuticals, Inc., USA; GE Healthcare, Ltd. Preparation of imidazo[1,2-a]pyridines and related compounds with activity at cannabinoid CB2 receptors. WO2008141249; 2008
   Google Scholar
• Acadia Pharmaceuticals, Inc., USA. Preparation of imidazo[1,2-a]pyridines and related compounds with activity at cannabinoid CB2 receptors. WO2008141239; 2008
   Google Scholar
• Forest Laboratories Holdings Limited, Bermuda. Preparation of imidazopyridine and imidazopyrimidine derivatives as cannabinoid receptor ligands. WO2008027812; 2008
   Google Scholar
• Forest Laboratories Holdings Limited, Bermuda. Preparation of imidazo[1,5-a]pyridine derivatives as cannabinoid receptor ligands. WO2008005908; 2008
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Preparation of benzimidazole derivatives as cannabinoid CB2 agonists. WO2008003665; 2008
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Benzimidazole derivatives as cannabinoid receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008119694; 2008
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Preparation of fluorinated alkyl-substituted benzimidazole derivatives as cannabinoid receptor agonists. WO2009077533; 2009
   Google Scholar
• Pfizer, Inc., Japan. Preparation of sulfonyl benzimidazole derivatives useful in treatment of diseases-mediated by CB2 receptor. WO2006094750; 2006
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Hexahydrocycloheptapyrazole compounds as cannabinoid modulators and their preparation, pharmaceutical compositions and use in the treatment of CB-mediated diseases. WO2008115705; 2008
   Google Scholar
• Cara Therapeutics, Inc., USA. Bridged phenanthridine derivatives as cannabinoid 2 receptors agonists or inverse agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008214537; 2008
   Google Scholar
• Cara Therapeutics, Inc., USA. Preparation of tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof as cannabinoid receptor ligands. WO2008079316; 2008
   Google Scholar
• Cara Therapeutics, Inc., USA. Preparation of benzo-fused heterocycles for preventing, inhibiting or treating a cannabinoid-associated disease. WO2009035997; 2009
   Google Scholar
• Cara Therapeutics, Inc., USA. Substituted imidazoheterocycle derivatives as cannabinoid receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of pain. US2009149450; 2009
   Google Scholar
• Merck & Co., Inc., USA. Decahydroquinoline analogs as CB2 receptor modulators, and therapeutic use. WO2008088744; 2008
   Google Scholar
• Merck & Co., Inc., USA. Preparation of imidazopyridine analogs as CB2 receptor modulators for treating pain, respiratory and non-respiratory diseases. WO2008085302; 2008
   Google Scholar
• Merck & Co., Inc., USA. Preparation of imidazo[1,5-a]pyridines as CB2 receptor ligands for treatment of pain. WO2009025785; 2009
   Google Scholar
• Merck & Co, Inc., USA. Substituted 1,2,4-oxadiazoles and analogs thereof as CB2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases. WO2009051705; 2009
   Google Scholar
• Bristol-Myers Squibb Company, USA. Preparation of indanyl indole amide compounds as CB2 agonists. WO2009015169; 2009
   Google Scholar
• Kalypsys, Inc., USA. Aminoquinazoline cannabinoid receptor modulators for treatment of disease and their preparation. WO2008157500; 2008
   Google Scholar
• Kalypsys, Inc., USA. Preparation of diazepine derivatives as cannabinoid receptor agonists. US2009062253; 2009
   Google Scholar
• University of Tennessee Research Foundation, USA. Preparation of tri-aryl/heteroaroaromatic cannabinoids and as receptor modulators. WO2008109027; 2008
   Google Scholar
• Bhattacharjee H, Gurley SN, Moore BM II. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. Bioorg Med Chem Lett 2009;19(6):1691-3
   PubMed Web of Science ®Google Scholar
• Adolor Corporation, USA. Pyridine compounds as cannabinoid receptor agonists and ligands and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008063625; 2008
   Google Scholar
• Adolor Corporation, USA. Sulfamoyl benzamides as cannabinoid receptor modulators and their preparation, pharmaceutical compositions. US7544676; 2009
   Google Scholar
• Goodman AJ, Ajello CW, Worm K, CB2 selective sulfamoyl benzamides: optimization of the amide functionality. Bioorg Med Chem Lett 2009;19(2):309-13
   PubMed Web of Science ®Google Scholar
• Pharmos Corporation, USA. Sulfonamide derivatives with therapeutic indications and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008075353; 2008
   Google Scholar
• Societe de Conseils de Recherches et d'Applications Scientifiques (SCRAS), Fr. Imidazo, pyrimido and diazepino pyrimidine-dione derivatives, their preparation, and their therapeutic use as ligands of CB2 receptors. WO2008090286; 2008
   Google Scholar
• Ipsen Pharma SAS, Fr. Preparation of 4-phenyl-1,3-azole derivatives, especially phenylthiazoles, and their use as ligands of CB2 receptors. WO2009071753; 2009
   Google Scholar
• Hoffmann-La Roche AG, F. Switz. Preparation of pyrazine-2-carboxamides as cannabinoid CB2 receptor ligands. WO2008040649; 2008
   Google Scholar
• Regents of the University of California, USA. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors. WO2008073130; 2008
   Google Scholar
• Cadila Healthcare Ltd., India. Preparation of indolecarboxylic acid trimethylbicycloheptylamides as cannabinoid CB2 receptor modulators. WO2009063495; 2009
   Google Scholar
• Insys Therapeutics Inc., USA. Oral cannabinoid liquid formulations and methods of treatment. WO2009020666; 2009
   Google Scholar
• Echo Pharmaceuticals BV, Neth. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances, such as cannabinoids. WO2008033024; 2008
   Google Scholar
• Alltranz Inc., USA. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same. WO2009018389; 2009
   Google Scholar
• Wine, Harvey, Can. Transdermal formulations of synthetic cannabinoids and nano-colloidal silica for pain treatment. WO2008006226; 2008
   Google Scholar
• GW Pharma Limited, UK. Cannabidiol for use in the treatment of transmissible neurodegenerative conditions. WO2009013506; 2009
   Google Scholar
• GW Pharma Limited, UK. Therapeutic uses of cannabigerol as CB1 and CB2 cannabinoid receptor agonists. WO2009001081; 2008
   Google Scholar
• GW Pharma Limited, UK. Cannabinoid-containing plant extracts for the treatment of inflammatory bowel disease. GB2450741; 2009
   Google Scholar
• GW Pharma Ltd., UK. New use for cannabinoid-containing plant extracts. WO2008129258; 2008
   Google Scholar
• Yissum Research Development Company of the Hebrew University of Jerusalem, Israel. Cannabinoid for the treatment of neuronal damage in diabetic patients. WO2008129529; 2008
   Google Scholar
• Virginia Common Wealth University, USA; Organix, Inc.; Temple University. Use of CB2 cannabinoid agonists for the treatment of central nervous system inflammation. US2008139635; 2008
   Google Scholar
• Wiley JL, Beletskaya ID, Ng EW, Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther 2002;301(2):679-89
   PubMed Web of Science ®Google Scholar
• Kyoto University, Japan. Pharmaceutical agent for prevention and treatment of skin disease induced by accelerated keratinization. WO2008111296; 2008
   Google Scholar
• Glenmark Pharmaceuticals, SA, Switz. Cannabinoid receptor modulators for treating non-immediate type allergic diseases. WO2008093194; 2008
   Google Scholar
• University of Plymouth, UK. Methods for slowing the progression of multiple sclerosis. US2008175902; 2008
   Google Scholar
• Yissum Research Development Company of the Hebrew University of Jerusalem, Israel; Hadasit Medical Research Services & Development Ltd.; Aristotle University of Thessaloniki. Methods and composition for prophylaxis and treatment of hepatic encephalopathy and liver cirrhosis. WO2008050344; 2008
   Google Scholar
• Pharmos Corporation, USA. Use of CB2 receptor agonists for promoting neurogenesis, and thereapeutic use thereof. WO2008001369; 2008
   Google Scholar
• Palazuelos J, Aguado T, Egia A, Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 2006;20(13):2405-7. doi: 10 1096/fj 06-6164fje
   PubMed Web of Science ®Google Scholar
• University of South Carolina, USA. Use of cannabidiol in the treatment of hepatitis. US2009005461; 2009
   Google Scholar
• Blum R. Pharmacological treatment of psoriasis. US2008255224; 2008
   Google Scholar
• Vanderbilt University. Cannabinoid receptor targeted agent. WO2009029727; 2009
   Google Scholar
• Bai M, Sexton M, Stella N, MBC94, a conjugable ligand for cannabinoid CB 2 receptor imaging. Bioconjug Chem 2008;19(5):988-92
   PubMed Web of Science ®Google Scholar
• California Pacific Medical Center, USA. Methods and compositions for treating cancer using a cannabinoid or derivative thereof. WO2008144475; 2008
   Google Scholar
• McAllister SD, Christian RT, Horowitz MP, Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007;6(11):2921-7
   PubMed Web of Science ®Google Scholar
• Combinatorx, Incorporated, USA; CHDI, Inc. Methods and compositions for the treatment of neurodegenerative disorders. WO2008133884; 2008
   Google Scholar
• Glaxo Group Limited, UK. Heteroaryl derivatives as CB2 ligand useful in combination with paracetamol in the treatment of CB2 mediated diseases and their preparation. WO2008116816; 2008
   Google Scholar
• University of Kentucky, USA. Novel synergistic opioid-cannabinoid codrug for pain management. WO2008045556; 2008
   Google Scholar
• Cichewicz DL, Martin ZL, Smith FL, Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999;289(2):859-67
   PubMed Web of Science ®Google Scholar
• Pharmaleads, Fr. New amino acid derivatives containing a disulfanyl group, particularly [[(aminoalkyl)dithio]alkanoyl]amino acids, their preparation, and their therapeutic use as mixed inhibitors of neprilysin and aminopeptisase N for treating depression and pain. US2009012153; 2009
   Google Scholar
• Abbott Laboratories. Combination therapy for reducing side effects using cannabinoid receptor ligands. WO2009052342; 2009
   Google Scholar
• STI Pharmaceuticals Ltd., UK. Pharmaceutical composition comprising cannabinoid and local anaesthetics for pulmonary administration. WO2009043395; 2009
   Google Scholar
• University of South Florida, USA. Synergistic modulation of microglial activation by nicotine and THC. WO2009059277; 2009
   Google Scholar
• Theraquest Biosciences, Inc. Pharmaceutical oral formulations of cannabinoids for decreasing potential abuse and toxicity. WO2008021394; 2008
   Google Scholar
• Theraquest Biosciences, Inc., USA. Multimodal abuse resistant and extended release formulations. WO2008033351; 2008
   Google Scholar
• Theraquest Biosciences, Inc., USA. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use for preventing the risk of cannabinoid agonist abuse and opioid agonist abuse. WO2008024490; 2008
   Google Scholar
• Available from: http://www.pharmoscorp.com/development/cannabinor.html [Last accessed 16 October 2009]
   Google Scholar